{'fraction_non_alphanumeric': 0.02090032154340836, 'fraction_numerical': 0.006430868167202572, 'mean_word_length': 5.1940298507462686, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
T cell therapy of human CMV and EBV infection in immunocompromised hosts

Acute virus infections in normal hosts are typically controlled by the development of a host immune response that includes MHC‐restricted virus‐specific T cells. Many viruses have developed methods to evade T cell recognition to facilitate initial infection and the establishment of a persistent infection in the host. Human cytomegalovirus (CMV) and Epstein‐Barr virus (EBV) are ubiquitous human pathogens that utilise novel strategies to evade immune elimination. Despite these evasion methods, CD4+ and CD8+ T cells expressing αβ T cell receptors have been shown to play a pivotal role in controlling initial infection and in maintaining CMV and EBV in a latent state. However, in settings of iatrogenic or acquired T cell deficiency, primary infection or reactivation of CMV and EBV frequently progresses to cause life threatening disease. In this article the role of MHC‐restricted CD8+ and CD4+ T cell responses in controlling CMV and EBV infections in healthy individuals and the development of novel strategies to restore protective T cell immunity to deficient hosts by the adoptive transfer of virus‐specific T cells is reviewed. © 1997 John Wiley & Sons, Ltd.